Evidence map›Paper›PMID 36906664›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

CD46 targeted

Jun Li, Tao Huang, Jun Hua, Qiong Wang, Yang Su, Ping Chen, Scott Bidlingmaier, Allan Li, Zhongqiu Xie, Anil P Bidkar and 9 more

Registry-linked trialOpen access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03575819 (A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer), which is not on this map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03575819 phase1completednot on this map

A Phase 1 Study of FOR46 Administered Every 21 Days in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

TypeinterventionalSponsorFortis Therapeutics, Inc.Ran2019 to 2023Enrolled56ConditionsProstate Cancer MetastaticArmsFOR46
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 37 citations in OpenAlex.

  1. Review
  2. Review
  3. Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  4. Preclinical Study of CDH3-TargetedMolecular pharmaceutics · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Article
  13. EJNMMI radiopharmacy and chemistry · 2025
    Review
  14. Article
  15. Article
  16. The multiverse of CD46 and oncologic interactions.The Journal of clinical investigation · 2025
    Review
  17. Current landscape and clinical progress of targeted alpha radioimmunotherapy.American journal of nuclear medicine and molecular imaging · 2025
    Review
  18. Article
  19. First-in-human SPECT/CT imaging of [European journal of nuclear medicine and molecular imaging · 2024
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Jun Li *Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
Tao Huang *Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
Jun HuaDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
Qiong WangDepartment of Urology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Yang SuDepartment of Anesthesia, University of California, San Francisco, CA, 94110, USA.
Ping ChenDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
Scott BidlingmaierDepartment of Anesthesia, University of California, San Francisco, CA, 94110, USA.
Allan LiDepartment of Anesthesia, University of California, San Francisco, CA, 94110, USA.
Zhongqiu XieDepartment of Pathology, University of Virginia, Charlottesville, VA, 22903, USA.
Anil P BidkarDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94110, USA.
Sui ShenDepartment of Radiation Oncology, University of Alabama, Birmingham, AL, 35233, USA.
Weibin ShiDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA.
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94110, USA.
Robert R FlavellDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA, 94110, USA.
Daniel GioeliDepartment of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, 22903, USA.
Robert DreicerUVA Comprehensive Cancer Center, University of Virginia, Charlottesville, VA, 22903, USA.
Hui LiDepartment of Pathology, University of Virginia, Charlottesville, VA, 22903, USA.
Bin LiuDepartment of Anesthesia, University of California, San Francisco, CA, 94110, USA. bin.liu@ucsf.edu.
Jiang HeDepartment of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, 22903, USA. jh6qv@virginia.edu.
University of Virginia · USUniversity of California, San Francisco · USChongqing Cancer Hospital · CNUCSF Helen Diller Family Comprehensive Cancer Center · USUniversity of Alabama at Birmingham · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Jay William FOX · 1987 to 2026
$72.1M
Novel radioimmunoconjugates for targeted alpha-particle therapy of metastatic prostatic cancerR01CA223767 · NCI · UNIVERSITY OF VIRGINIA · PI HE, JIANG, LIU, BIN · 2018 to 2022
$2.8M
Genetic connections between type 2 diabetes and atherosclerosisR01DK116768 · NIDDK · UNIVERSITY OF VIRGINIA · PI SHI, WEIBIN · 2019 to 2022
$1.6M
Trimodal PET/SPECT/CT Preclinical Scanner for Biomedical ResearchS10OD021672 · OD · UNIVERSITY OF VIRGINIA · PI BERR, STUART S. · 2016 to 2016
$1.2M
National Institute of Health S10OD021672NCI NIH HHS CCSG P30 CA44579NCI NIH HHS P30 CA044579NCI NIH HHS R01 CA223767NCI NIH HHS R01CA223767NIDDK NIH HHS R01 DK116768NIH HHS S10 OD021672
6 · The paper itself

Abstract

We recently identified CD46 as a novel prostate cancer cell surface antigen that shows lineage independent expression in both adenocarcinoma and small cell neuroendocrine subtypes of metastatic castration resistant prostate cancer (mCRPC), discovered an internalizing human monoclonal antibody YS5 that binds to a tumor selective CD46 epitope, and developed a microtubule inhibitor-based antibody drug conjugate that is in a multi-center phase I trial for mCRPC (NCT03575819). Here we report the development of a novel CD46-targeted alpha therapy based on YS5. We conjugated

Indexed as

Prostatic Neoplasms, Castration-ResistantRadioimmunotherapyAlpha ParticlesAnimalsHumansLeadLead RadioisotopesMaleMembrane Cofactor ProteinCD46 protein, humanLeadLead RadioisotopesMembrane Cofactor Protein212PbCD46 epitopeHuman monoclonal antibodymCRPCProstate cancerProstate cancer patient-derived xenograft modelRadioimmunotherapyTargeted alpha therapy

Identifiers

PMID36906664
PMCPMC10007843
OpenAlexW4323971746

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read34
identifiers read6
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.